DIFFERENCES VALUE OF BLOOD UREA NITROGEN AND CREATININE SERUM IN CERVICAL CANCER SQUAMOUS CELL STADIUM IIB-IIIB BEFORE AND AFTER CHEMOTHERAPY PACLITAXEL CISPLATIN FOR SIX CYCLE IN SANGLAH GENERAL HOSPITAL DENPASAR BALI

摘要

Objectives: The combination of paclitaxel-cisplatin regimen is one of the chemotherapy regimen used at Sanglah General Hospital, Denpasar. Cisplatin is a potent chemotherapeutic agent, but the nephrotoxic effects of cisplatin reportedly given that research is needed to see the toxic effect on the kidneys before and after 6 series of paclitaxel-cisplatin chemotherapy. Toxicity assessment of the chemotherapy can be seen by evaluating kidney function from monitoring both blood urea nitrogen (BUN) and creatinine serum value. Methods: The research is conducted as an observational study using a prospective cohort method. The research was conducted from January 2016 to June 2016. Patient’s follow-up was conducted from the first until the last series of chemotherapy. The data was statistically analyzed with STATA version 14 with paired t test when the data was normally distributed or was analyzed with Wilcoxon test when the data was not normally distributed. Results: A total of seven patients were evaluated of both their BUN and creatinine serum value during six series of chemotherapy. Statistically, the BUN and creatinine serum value before the first and after the last paclitaxel-cisplatin chemotherapy series are not significantly different (p> 0.05). Conclusion: There are no significant changes of both BUN and creatinine serum value before the first and after the last paclitaxel-cisplatin chemotherapy series in patients with stadium IIB-IIIB squamous cell cervical cancer. Research with larger sample size is essential to provide optimal information for other healthcare professionals. Keywords: cervical cancer, paclitaxel-cisplatin, creatinine serum, BUN